JP2006515626A5 - - Google Patents

Download PDF

Info

Publication number
JP2006515626A5
JP2006515626A5 JP2006500976A JP2006500976A JP2006515626A5 JP 2006515626 A5 JP2006515626 A5 JP 2006515626A5 JP 2006500976 A JP2006500976 A JP 2006500976A JP 2006500976 A JP2006500976 A JP 2006500976A JP 2006515626 A5 JP2006515626 A5 JP 2006515626A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
use according
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006500976A
Other languages
English (en)
Other versions
JP4852409B2 (ja
JP2006515626A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/001089 external-priority patent/WO2004064826A1/en
Publication of JP2006515626A publication Critical patent/JP2006515626A/ja
Publication of JP2006515626A5 publication Critical patent/JP2006515626A5/ja
Application granted granted Critical
Publication of JP4852409B2 publication Critical patent/JP4852409B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (1)

  1. 化合物が：

    であるか、またはその薬学的に許容されうる塩である請求項１または１２記載の使用。
JP2006500976A 2003-01-15 2004-01-15 多剤耐性癌を治療するためのビス（チオヒドラジドアミド）化合物 Expired - Fee Related JP4852409B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44040603P 2003-01-15 2003-01-15
US60/440,406 2003-01-15
PCT/US2004/001089 WO2004064826A1 (en) 2003-01-15 2004-01-15 Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer

Publications (3)

Publication Number Publication Date
JP2006515626A JP2006515626A (ja) 2006-06-01
JP2006515626A5 true JP2006515626A5 (ja) 2007-06-14
JP4852409B2 JP4852409B2 (ja) 2012-01-11

Family

ID=32771813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006500976A Expired - Fee Related JP4852409B2 (ja) 2003-01-15 2004-01-15 多剤耐性癌を治療するためのビス（チオヒドラジドアミド）化合物

Country Status (14)

Country Link
US (1) US7763658B2 (ja)
EP (1) EP1583524B1 (ja)
JP (1) JP4852409B2 (ja)
AT (1) ATE336991T1 (ja)
AU (1) AU2004206865B2 (ja)
CA (1) CA2512797C (ja)
CY (1) CY1106246T1 (ja)
DE (1) DE602004002087T2 (ja)
DK (1) DK1583524T3 (ja)
ES (1) ES2271839T3 (ja)
HK (1) HK1084024A1 (ja)
PT (1) PT1583524E (ja)
TW (1) TWI330079B (ja)
WO (1) WO2004064826A1 (ja)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
MXPA06011219A (es) 2004-03-29 2007-05-08 Univ South Florida Tratamiento efectivo de tumores y cancer con triciribina y compuestos relacionados.
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US7385084B2 (en) 2004-06-23 2008-06-10 Synta Pharmaceutical Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
WO2006033913A2 (en) * 2004-09-16 2006-03-30 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amides) for treament of hyperplasia
EP1827410A2 (en) * 2004-11-19 2007-09-05 Synta Pharmaceuticals Corporation Bis(thio-hydrazide amides) for increasing hsp70 expression
WO2006062732A2 (en) * 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
WO2006113572A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
US8017654B2 (en) 2005-04-15 2011-09-13 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
KR20080008399A (ko) * 2005-05-16 2008-01-23 신타 파마슈티칼스 코프. 비스(티오-히드라지드 아미드) 염의 합성 방법
RU2433822C2 (ru) * 2005-08-16 2011-11-20 Синта Фармасьютиклз Корп. Композиция бис(тио-гидразид амида)
JP2010501562A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
CA2661440A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
AU2007288334A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
US20080176828A1 (en) * 2006-08-21 2008-07-24 Martin Williams Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
WO2008024298A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
AU2007288340A1 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
EP2076254A2 (en) 2006-08-31 2009-07-08 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
US20080118562A1 (en) * 2006-09-11 2008-05-22 Keizo Koya Bis(thiohydrazide amides) formulation
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
TW200829543A (en) * 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
WO2009064374A2 (en) * 2007-11-09 2009-05-22 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
US8637704B2 (en) * 2007-11-28 2014-01-28 Synta Pharmaceuticals Corp. Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide)
US8581004B2 (en) 2008-02-21 2013-11-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009123704A2 (en) * 2008-03-31 2009-10-08 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
MX2011004276A (es) 2008-10-22 2011-06-27 Synta Pharmaceuticals Corp Complejos de metales de transicion de compuestos bis (tiohidrazida amida).
EP2373624A4 (en) * 2008-10-22 2014-06-11 Synta Pharmaceuticals Corp TRANSITION METAL COMPLEXES OF A TO [THIOHYDRAZIDAMID] COMPOUND
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
AU2009322603B2 (en) 2008-12-01 2013-08-29 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2011069159A2 (en) 2009-12-04 2011-06-09 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
US8815945B2 (en) 2010-04-20 2014-08-26 Masazumi Nagai Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
JP2014534238A (ja) * 2011-11-10 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス（チオヒドラジドアミド）化合物の投与
US20130149392A1 (en) 2011-12-12 2013-06-13 Synta Pharmaceuticals Corp. Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2097737A5 (en) 1970-07-14 1972-03-03 Berlin Chemie Veb Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4-
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB1272920A (en) 1971-03-15 1972-05-03 Berlin Chemie Veb New thiosemicarbazides
US4012360A (en) 1973-12-03 1977-03-15 Ciba-Geigy Corporation Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines
JPS5091056A (ja) 1973-12-17 1975-07-21
US4822777A (en) 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
JP2767241B2 (ja) * 1987-04-15 1998-06-18 ロ−ム アンド ハ−ス コンパニ− 殺虫性のｎ−（場合により置換された）−ｎ′−置換−ｎ，ｎ′−ジ置換ヒドラジン
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
AU673057B2 (en) 1993-02-22 1996-10-24 Abraxis Bioscience, Llc Methods for (in vivo) delivery of biologics and compositionsuseful therefor
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5840746A (en) 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5523325A (en) * 1993-09-09 1996-06-04 Jacobson; Richard M. Amidrazones and their use as pesticides
CA2191999A1 (en) * 1994-06-03 1995-12-14 Oliver Wagner Carbamoyl carboxylic acid hydrazides and their use against fungi
JP3535177B2 (ja) 1995-09-22 2004-06-07 バイオイメージ・アクティーゼルスカブ 緑色蛍光性タンパクであるｇｆｐの新規な変種
US5739686A (en) 1996-04-30 1998-04-14 Naughton; Michael J. Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection
US6235787B1 (en) 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
TW479053B (en) 1998-10-19 2002-03-11 Agro Kanesho Co Ltd Hydrazineoxoacetamide derivatives and pesticides
ES2161594B1 (es) 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
US6322303B1 (en) 2000-05-12 2001-11-27 David M. John Dunnage bag and method of making same
EP1164126A1 (de) 2000-06-16 2001-12-19 Basf Aktiengesellschaft Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen
US6365745B1 (en) 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
JP2004532187A (ja) 2001-01-25 2004-10-21 ギルフォード ファーマシュウティカルズ インコーポレイテッド 三置換カルボサイクリックサイクロフィリン結合化合物とその用途
WO2002087585A1 (en) * 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
WO2002094259A1 (en) 2001-05-03 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US6602907B1 (en) 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6924312B2 (en) 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
BR0214553A (pt) 2001-11-28 2004-10-13 Sod Conseils Rech Applic Compostos, processo de preparação, em fase lìquida, dos compostos, e, composições farmacêuticas
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
AU2006228035B2 (en) 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
CA2515726C (en) 2003-02-11 2012-07-10 Vernalis (Cambridge) Limited Isoxazole compounds
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
KR100544347B1 (ko) 2003-12-11 2006-01-23 한국생명공학연구원 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
EP1730124A4 (en) 2004-03-26 2009-04-01 Amphora Discovery Corp Certain compounds based on triazole, compositions and applications thereof
US7385084B2 (en) 2004-06-23 2008-06-10 Synta Pharmaceutical Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
WO2006033913A2 (en) 2004-09-16 2006-03-30 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amides) for treament of hyperplasia
EP1827410A2 (en) 2004-11-19 2007-09-05 Synta Pharmaceuticals Corporation Bis(thio-hydrazide amides) for increasing hsp70 expression
WO2006062732A2 (en) 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
CN101142198B (zh) 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
WO2006113493A2 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
WO2006113572A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
US8017654B2 (en) 2005-04-15 2011-09-13 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
KR20080008399A (ko) 2005-05-16 2008-01-23 신타 파마슈티칼스 코프. 비스(티오-히드라지드 아미드) 염의 합성 방법
RU2433822C2 (ru) 2005-08-16 2011-11-20 Синта Фармасьютиклз Корп. Композиция бис(тио-гидразид амида)
JP5441690B2 (ja) 2006-05-25 2014-03-12 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
CA2661440A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
JP2010501562A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
WO2008024298A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
US20080176828A1 (en) 2006-08-21 2008-07-24 Martin Williams Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
AU2007288340A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
AU2007288334A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
EP2076254A2 (en) 2006-08-31 2009-07-08 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
US20080118562A1 (en) 2006-09-11 2008-05-22 Keizo Koya Bis(thiohydrazide amides) formulation
EP2059250A2 (en) 2006-09-14 2009-05-20 Synta Pharmaceuticals Corporation Compounds for the treatment of angiogenesis
TW200829543A (en) 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
US20090093538A1 (en) 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
US8729111B2 (en) 2007-08-07 2014-05-20 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders

Similar Documents

Publication Publication Date Title
JP2006515626A5 (ja)
JP2007522220A5 (ja)
JP2009502793A5 (ja)
JP2006526031A5 (ja)
JP2009535462A5 (ja)
JP2005518413A5 (ja)
JP2008513510A5 (ja)
JP2010501534A5 (ja)
JP2009149903A5 (ja)
JP2011518833A5 (ja)
JP2008517059A5 (ja)
JP2007503202A5 (ja)
JP2008506632A5 (ja)
JP2010529196A5 (ja)
JP2006240292A5 (ja)
JP2008501714A5 (ja)
JP2003503454A5 (ja)
JP2005247844A5 (ja)
JP2006188651A5 (ja)
JP2008514623A5 (ja)
JP2007520565A5 (ja)
JP2009520682A5 (ja)
JP2007070320A5 (ja)
JP2006518752A5 (ja)
JP2011519871A5 (ja)